NIH-funded research R01 grant

Host-targeted therapy to prevent lung injury from pneumonia-caused sepsis

Official title: Inflammatory Organ Injury after Pneumonia-Derived Sepsis

Funded at Louisiana State Univ A&m Col Baton Rouge · NIH-11332285 · Data updated 2026-11-12

A patient-focused look at how boosting the body’s own defenses in the lungs could lessen lung and organ damage during severe pneumonia linked to sepsis from bacteria.

More Sepsis research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionLouisiana State Univ A&m Col Baton Rouge
NIH-funded
Lab location1 site (Baton Rouge, United States)
Project startJuly 1, 2024
Project endMay 31, 2029
Funding year2026
Award (this year)$715,216
NIH project number5R01AI180123-03
Project IDNIH-11332285 on NIH RePORTER

Who could benefit from this research

Could help

Patients with severe pneumonia and sepsis, particularly those at risk for acute lung injury and ARDS.

Less likely to help

Patients without pneumonia-derived sepsis or ARDS may not directly benefit from this specific line of investigation.

What this research studies

This project aims to understand how activating a protective pathway in the lungs helps the body fight a dangerous bacterial infection and reduce ARDS-related injury. Researchers plan to study how the immune system’s responses interact with pneumonia-causing bacteria and how this affects lung health, with an emphasis on the Nrf2 pathway. The work will explore potential host-targeted strategies that could complement antibiotics to prevent organ injury in patients with CRKP-related pneumonia. If successful, these findings could inform new treatment approaches to lower mortality and long-term complications from severe lung infections.

Why it matters

Potential benefit: If successful, the research could lead to host-directed therapies that reduce lung injury and improve survival for patients with pneumonia-related sepsis and ARDS.

How similar studies have gone: Previous work has shown that immune pathways can influence lung injury in infections, but translating this to targeted host therapies remains investigational.

Where this research is happening

  • Louisiana State Univ A&m Col Baton Rouge
    Baton Rouge, United States
    Active

Researchers

  • Principal investigator: Jeyaseelan, Samithamby — Louisiana State Univ A&m Col Baton Rouge
  • Study coordinator: Jeyaseelan, Samithamby

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.